Prostate Cancer Clinical Trial

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Summary

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
Clinically localized (no evidence on clinical or imaging studies of advanced disease).
No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
Sufficient amount of tissue remains from biopsy to perform genomic testing.

Exclusion Criteria:

Patients with a known history of hypogonadism

Study is for people with:

Prostate Cancer

Estimated Enrollment:

1270

Study ID:

NCT01954004

Recruitment Status:

Completed

Sponsor:

Myriad Genetic Laboratories, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Salt Lake City Utah, , United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

1270

Study ID:

NCT01954004

Recruitment Status:

Completed

Sponsor:


Myriad Genetic Laboratories, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider